Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Key Resources and Organizations for Precision Medicine Guidelines

Home
/
update
/
details

Singapore's NPM Programme Partners with PacBio to Advance HiFi Sequencing in Southeast Asia

NextEdge Admin

06 Aug 2024

2 min 28 sec

PacBio , a leader in high-quality sequencing solutions, has been selected by Precision Health Research, Singapore (PRECISE) for its Long-Read Sequencing Flagship Project. This initiative, part of Singapore’s National Precision Medicine (NPM) programme, aims to create the largest long-read sequencing dataset in Southeast Asia, advancing precision medicine in Singapore by providing new insights into the Asian genome.

The partnership utilizes PacBio’s Revio HiFi sequencing system, known for its comprehensive genomic coverage and ability to detect large structural variations and DNA methylation. This technology will enable detailed analysis of genetic diversity, disease mechanisms, and clinical diagnoses within Singapore’s multi-ethnic population. The multi-omics approach combines whole genome sequencing, RNA full-length sequencing, fiber sequencing, and methylation analysis.

Christian Henry, President and CEO of PacBio, expressed his enthusiasm for the collaboration, highlighting the system's capability to deliver complete and accurate genomes. The project will generate phased methylome and genomic data with specific HiFi depth for various applications, including reference genomes, multi-omics analysis, and research cases in cancer and rare diseases.

PacBio will establish advanced sequencing infrastructure in Singapore, featuring a centralised library preparation facility and sequencing laboratory. Macrogen Asia Pacific Pte Ltd, a CAP-accredited service provider, will handle the sequencing production. Data integration and secure access will be managed through AWS cloud storage.

This partnership represents a significant commitment from both PacBio and PRECISE to drive scientific breakthroughs and enhance clinical outcomes in precision medicine, leveraging cutting-edge technology and local expertise to shape the future of healthcare in Singapore and beyond.